Exponent vs Franklin Covey
EXPO and FC side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXPO and FC compare
Exponent is the larger company, worth 28 times as much as Franklin Covey ($4.2B against $151M).
On earnings, Exponent is cheaper: it trades at 39.3× trailing earnings, against 83.6× for Franklin Covey.
Exponent grew revenue faster over the last twelve months (12.8% versus −6.1% for Franklin Covey).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 0.83% at Franklin Covey.
Exponent pays a dividend yielding 1.4%; Franklin Covey does not pay one.
Exponent scores higher on the StockData Score (20 against 9 for Franklin Covey), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXPO | FC |
|---|---|---|
| Size and price | ||
| Market cap | $4.2B | $151M |
| Share price | $87.69 | $13.37 |
| Change, 1 year | 25.4% | −10.8% |
| Change, 5 years | −24.9% | −70.4% |
| Beta (5Y) | 0.24 | 1.36 |
| Employees | 1,313 | 1,120 |
| StockData Score | ||
| Total score | 20 (better) | 9 |
| Valuation score | 2 | 2 |
| Growth score | 3 (better) | 0 |
| Performance score | 5 (better) | 3 |
| Health score | 6 (better) | 4 |
| Dividend score | 4 (better) | 0 |
| Valuation | ||
| P/E | 39.3× (better) | 83.6× |
| P/S | 6.6× | 0.6× (better) |
| P/B | 14.4× | 3.5× (better) |
| EV/EBITDA | 29.8× | 21.6× (better) |
| P/FCF | 38.4× | 7.8× (better) |
| PEG | 21.41 | – |
| FCF yield | 2.6% | 12.8% (better) |
| Fair value | $66.46 | $16.41 |
| Margin of safety | −31.9% | 18.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | −6.1% |
| Revenue growth, 5Y average | 7.8% (better) | 6.1% |
| Net income growth (TTM) | 8.7% (better) | −79.5% |
| EPS growth (TTM) | 11.5% (better) | −79.7% |
| EPS growth, 5Y average | 6.0% | – |
| Profitability | ||
| Gross margin | – | 75.2% |
| Operating margin | 20.2% (better) | 2.4% |
| Net margin | 17.7% (better) | 0.83% |
| FCF margin | 17.2% (better) | 7.3% |
| Return on equity | 31.2% (better) | 4.0% |
| Return on invested capital | 43.8% (better) | 10.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | 19.1× |
| Current ratio | 1.98 (better) | 0.66 |
| Altman Z-score | 10.26 (better) | 2.60 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | – |
| Payout ratio | 54.8% | – |
| Years of dividend growth | 13 | – |
| Dividend growth, 5Y average | 9.6% | – |
| Buyback yield | 5.1% | 20.9% (better) |
| Shareholder yield | 6.5% | 20.9% (better) |
| Ownership | ||
| Held by institutions | 97.8% | 72.6% |
| Held by insiders | 1.3% | 44.5% |
| Insider net buying, 12 months | −$2.7M | −$123K (better) |
| Short interest, % of float | 5.2% | 13.2% |
Go deeper
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
- FC stock overview
- FC income statement
- FC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.